U.S. Markets closed

MYOS RENS Technology Inc. (MYOS)

NASDAQ Capital Market - NASDAQ Capital Market Delayed Price. Currency in USD
Add to watchlist
1.2699-0.0001 (-0.0079%)
At close: 3:59PM EDT
People also watch
PULMBNTCDFFNNAKDZAIS
  • J
    Jermayne
    Jermayne

    This is where I find the top NASDAQ & NYSE Trade Ideas ---> www.T0pm@rketgainers.c0m

  • b
    bob
    bob
    zzzzzzzzz zzzzzzz
  • Y
    Yong
    Yong
    huge tomorrow!!
  • A
    Anonymous
    Anonymous

    IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • R
    Roxanne
    Roxanne
    MYOS, looks to be overvalued at this price Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awe.some.stock_s.
  • Y
    Yong
    Yong
    $5 is a reasonable price
  • C
    Connie
    Connie
    The scenarios are quite interesting at current levels for MYOS. Not sure how awesome_stock.s finds all these incredible trade ideas but im happy.
  • S
    Sheila
    Sheila
    Who says MYOS isn't poised for potentially massive upward movement? Yo you should really check out awe.some.stock.s, they seem on point with their stocks.
  • K
    Kathy
    Kathy
    Very difficult to see MYOS not making a big run north. google awesomeS-TOCKS - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
  • m
    mr
    mr
    another tanker underway...
  • i
    inbal
    inbal
    So what's the reason for this climbing? No news and yet... share your thoughts, got 1000 for 2.3
  • D
    Daniel
    Daniel
    almost 10% up? wonder what is going on
  • i
    inbal
    inbal
    Should I stay or should I go now....🤔
  • M
    Mark
    Mark
    Now it's a good price. Buying 2000shares and holding to Q3
  • b
    bob
    bob
    I don't really understand the rights plan. Any help out there
  • D
    Daniel
    Daniel
    Any recent news, the stock has been floating between 2 and 3 and is still a bit undervalued in my opinion.
  • C
    Cole
    Cole
    Product release today, any thoughts on how that will affect the price? I assume it will pump a bit.
  • r
    rOB
    rOB
    Who else got the top-market/gainer alert this morning?
  • B
    Ben Victoria
    Ben Victoria
    Just got an alert for this stock today. It has been on my watchlist for a while so I'm in at this low price
  • b
    bettertrader
    bettertrader
    reach $4.20 sold if luck otherwise that about it, $3.85 that highest of the day, crazy buy, tried jump in but the price went up like sky rock now what it went down...how about that?